Comparative Pharmacology
Head-to-head clinical analysis: PRILOSEC OTC versus ZEGERID OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRILOSEC OTC versus ZEGERID OTC.
PRILOSEC OTC vs ZEGERID OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
20 mg orally once daily before a meal for 14 days for frequent heartburn; 20 mg orally once daily for up to 8 weeks for erosive esophagitis healing; 20 mg orally once daily for maintenance of healed erosive esophagitis (up to 12 months).
None Documented
None Documented
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Terminal half-life approximately 1.5-2 hours (0.5-1 hour in children); due to short half-life, acid suppression duration is prolonged via irreversible proton pump inhibition
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Renal (80% as metabolites) and fecal (20%)
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor